Trial ID: NCT05356312
Interventional - EAP - Available
The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.
Zentrum fur Humangenetik Tuebingen
Last updated: ยท Source: Clinicaltrials.gov